Placebo: First dose at 0 hours
OtherVehicle (ultrapure water with 10 % fish sauce), orally administered
NCT Number: NCT07771166
This study is an investigator-initiated, randomised, double-blind, placebo-controlled, cross-over human trial investigating the effect of arachidonoyl-taurine (C20:4-taurine) and oleoyl-taurine (C18:1-taurine) on GLP-1 secretion during fasting and feeding.
Trial opening soon.
Get Notified18 year–45 year
All sexes
Interventional
Not applicable
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Vehicle (ultrapure water with 10 % fish sauce), orally administered
Arachidonoyl-taurine (2 mg/kg) dissolved in ultrapure water with 10 % fish sauce, orally administered
Oleoyl-taurine (2 mg/kg) dissolved in ultrapure water with 10 % fish sauce, orally administered
Liquid meal with 1.5 g paracetamol. Administered with a second dose of: Vehicle (ultrapure water with 10 % fish sauce), orally administered
Liquid meal with 1.5 g paracetamol. Administered with a second dose of: Oleoyl-taurine (2 mg/kg) dissolved in ultrapure water with 10 % fish sauce, orally administered
Liquid meal with 1.5 g paracetamol. Administered with a second dose of: Arachidonoyl-taurine (2 mg/kg) dissolved in ultrapure water with 10 % fish sauce, orally administered
Time frame: 0-360 minutes
Incremental area under curve 0-360 minutes
Time frame: 0-360 minutes
Difference in plasma concentration between interventions
Time frame: 0-360 minutes
Difference in plasma concentration between interventions
Time frame: 0-360 minutes
Difference in plasma concentration between interventions
Time frame: 0-360 minutes
Difference in plasma concentration between interventions
Time frame: 0-360 minutes
Difference in plasma concentration between interventions
Time frame: 0-360 minutes
Difference in plasma concentration between interventions
Time frame: 0-360 minutes
Visual analogue scales are 10 cm long lines. Participants will score their subjective perception of their hunger, satiety, thirst, nausea and well-being from 0 cm (none/bad) to 10 cm (the most amount/good).
Time frame: After 360 minutes
Amount of provided meal consumed
Time frame: 180-360 minutes
Difference in plasma concentration between interventions
Time frame: 0-360 minutes
Difference in plasma concentration between interventions
Time frame: 0-360 minutes
Difference in plasma concentration between interventions
Time frame: 0-360 minutes
Difference in plasma concentration between interventions
Time frame: 0-360 minutes
Difference in plasma concentration between interventions
Time frame: 0-360 minutes
Difference in plasma concentration between interventions
Time frame: 0-360 minutes
Difference in plasma concentration between interventions
Time frame: 0-360 minutes
Gallbladder volume assessed by ultrasonography
Time frame: Baseline
Nucleobase sequence of the fatty acid amide hydrolase gene region of the DNA.
Time frame: Baseline
Nucleobase sequence of the G-protein coupled receptor 119 gene region of the DNA.
Time frame: 0-360 minutes
Difference in plasma concentration between interventions
University Hospital, Gentofte, Copenhagen
Other
Effects of N-Acyl Taurines on Incretin Levels in Healthy Subjects: a Randomised, Double-blind, Placebo-controlled, Cross-over Study
Acronym: NAT-INC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05654142
Body Weight, CARDIOMETABOLIC CONDITIONS
Chicago, Illinois, United States
View Trial DetailsNCT07387393
Body Weight, CARDIOMETABOLIC CONDITIONS
Fayetteville, Arkansas, United States
View Trial DetailsNCT06813092
Behavior, Bone Diseases
Erlangen, Germany
View Trial DetailsNCT06878885
Behavior, Behavioral Symptoms
Browning, Montana, United States
View Trial Details